Ultreo

About Ultreo

Ultreo Inc. emerged in the consumer oral care market, focusing on advanced toothbrush technology. The company was spearheaded by entrepreneur Jack Gallagher, who previously served as president of Optiva Corporation, the developer of the Sonicare toothbrush. The foundational technology for Ultreo was conceived in 2003 by Pierre Mourad, a research scientist at the University of Washington's Applied Physics Laboratory and Department of Neurological Surgery. Mourad hypothesized that integrating ultrasound with conventional sonic bristle action could enhance plaque removal. Gallagher recognized the potential to innovate within the power toothbrush category, and together they developed the concept.

The firm's core product was the Ultreo toothbrush, which uniquely combined sonic bristle motion with a proprietary ultrasound waveguide. While the sonic bristles functioned to physically remove plaque and generate foam, the waveguide channeled ultrasound energy to activate the bubbles, creating a pulsating action intended to disrupt plaque bacteria in hard-to-reach areas. This combination of technologies was the company's primary differentiator in the competitive power toothbrush market. The product's development was supported by grants from the Washington Technology Center and the National Institutes of Health (NIH), as well as over $11 million in venture financing. The toothbrush featured a two-minute timer with 30-second intervals, a brush head replacement indicator, and a battery life of up to 28 uses on a full charge.

Ultreo targeted consumers seeking a more advanced and effective cleaning experience than what was available from existing power toothbrushes. The business model centered on the direct sale of the toothbrush, which retailed for around $149-$169, and recurring revenue from replacement brush heads. The company launched its product in 2007 and quickly attracted attention, leading to a legal battle with Procter & Gamble over advertising claims regarding the efficacy of its ultrasound technology. Despite demonstrating promising early results in laboratory studies and raising significant capital, Ultreo faced challenges. After a period of legal disputes and attempts to secure further investment, the company ceased production in 2012.